Completed PHASE1 INTERVENTIONAL 1-arm NCT02056782

A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia (PGX-AML)

A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia

Sponsor: Jazz Pharmaceuticals

Conditions Acute Myeloid Leukemia

Interventions Dociparstat sodium

Updated 8 times since 2017 Last updated: May 20, 2022 Started: Dec 31, 2013 Primary completion: Feb 28, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Acute Myeloid Leukemia and is currently completed. Jazz Pharmaceuticals leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Nov 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Nov 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2023 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Mar 2023 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jazz Pharmaceuticals
Translational Drug Development

Data source: Jazz Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.